ClinicaliQ Trial Snapshot
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors — Recruiting • Phase I • Oncology • NCT06545942.
- What is being tested: MOMA-313, an oral therapeutic agent, is undergoing Phase 1 evaluation for safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity in patients with advanced or metastatic solid tumours, with assessments of both single-agent and combination therapy approaches.
- Patient eligibility overview: This multi-centre, open-label study recruits patients with advanced or metastatic solid tumours; detailed eligibility criteria determine suitability for dose escalation and optimisation cohorts within the trial framework.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Eligibility Snapshot
- Key Inclusion Criteria: 1. Age ≥ 18 years 2. Have histologically confirmed disease for each treatment arm as follows: 1. Treatment Arm 1 (MOMA-313 Monotherapy) - Advanced (including locally), relapsed or metastatic solid tumors that are not eligible for curative therapy, with any HR-deficient alteration. 2. Treatment Arm 2 (MOMA-313 in Combination with Olaparib): * Dose escalation: Advanced (including locally), relapsed or metastatic solid tumors that are not eligible for curative therapy, for which a PARP inhibitor is indicated, with select HR-deficient mutations. Patients may be PARP inhibitor naive or exposed. * Dose optimization: Advanced (including locally), relapsed or metastatic CRPC or pancreatic ductal adenocarcinoma (PDAC) with select HR-deficient mutations. Patients must be PARP inhibitor naive. 3. Have at least 1 lesion at baseline (measurable or non-measurable) suitable for repeat imaging evaluation by RECIST and/or PCWG-3 4. ECOG PS ≤ 2 5. Fully recovered from clinically relevant effects of prior therapy, radiotherapy, and/or surgery **hormonal therapy allowed. Palliative radiotherapy allowed. 6. Adequate organ function per local labs 7. Comply with contraception requirements 8. Written informed consent must be obtained according to local guidelines Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.